NASDAQ · PPCB
Propanc Biopharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PPCB: Nov 13, 2026
Propanc Biopharma, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-97.5.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews- RTTNews · Oct 22, 2:00 PM EDTPropanc Biopharma Sets 1-for-10 Reverse Stock Split For October 26; Stock Down(RTTNews) – Propanc Biopharma (PPCB) announced that its Board of Directors has approved a 1-for-10 reverse stock split of the company's issued and outstanding common shares, aimed at restoring compliance with Nasdaq's continued listing requirements, including the $1.00 minimum bi
- RTTNews · Oct 18, 8:11 PM EDTPropanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27(RTTNews) – Propanc Biopharma Inc. (PPCB), a biopharmaceutical company, on Friday announced preclinical data for a formulation of pancreatic pro-enzymes (PRP) in treating pancreatic and ovarian cancer.
- RTTNews · Oct 8, 3:40 AM EDTPropanc Reports Positive Preclinical Pancreatic Cancer Data For PRP; Phase 1b Planned In Q1 2027(RTTNews) – Propanc Biopharma, Inc. (PPCB), a biopharmaceutical company, highlighted new preclinical data for its lead investigational candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and compared that profile with a clinical standard recently established by Revolution Me
- RTTNews · Sep 9, 10:33 AM EDTPPCB Advances PRP Toward Phase 1b Study; Trial Start Planned For February 2027(RTTNews) – Propanc Biopharma, Inc. (PPCB) announced plans to initiate a world-first Phase 1b first-in-human (FIH) clinical study of PRP in February 2027 for patients with advanced solid tumors.
- RTTNews · Aug 28, 10:42 AM EDTWeekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal(RTTNews) – This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing collaborations, and mixed clinical trial readouts.
- RTTNews · Aug 27, 2:52 PM EDTBiotech Gainers: PPCB And CELU Lead Rally On Company-Specific Catalysts(RTTNews) – Today's top gainers in the biotech and healthcare space include Propanc Biopharma, following strong preclinical pancreatic cancer data; VolitionRx, after positive validation of its Nu.Q NETs biomarker; Nutanix, on higher quarterly revenue and profit; Xtant Medical, fo
- RTTNews · Aug 27, 10:01 AM EDTPropanc Reports >90% Tumor Growth Inhibition In Preclinical Pancreatic Cancer Study; Shares Surge(RTTNews) – Propanc Biopharma, Inc. (PPCB), has unveiled new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma.
- RTTNews · Aug 27, 9:35 AM EDTPropanc Biopharma Announces Positive Preclinical Data For PRP In Pancreatic Cancer, Stock Soars(RTTNews) – Thursday, Propanc Biopharma, Inc. (PPCB) announced compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma or PDAC.
- RTTNews · Aug 18, 10:29 AM EDTPropanc Advances PRP Toward First-In-Human Phase 1b Study In Advanced Solid Tumors(RTTNews) – Propanc Biopharma, Inc. (PPCB) announced that it has begun finalizing the clinical trial protocol and conducting a feasibility assessment for its planned First-In-Human (FIH) Phase 1b study of PRP in up to 40 patients with advanced solid tumors.
- RTTNews · Aug 12, 1:02 PM EDTPropanc Advances PRP Toward Phase 1b Study In Advanced Solid Tumors; Stock Up(RTTNews) – Propanc Biopharma, Inc. (PPCB), a biopharmaceutical company developing therapies for chronic diseases including recurrent and metastatic cancer, highlighted the differentiated mechanism of its lead candidate PRP compared with RAS-targeted approaches being developed by
- RTTNews · Jul 8, 1:27 AM EDTPropanc Biopharma Signs MOU With Avance Clinical To Advance First-in-Human Trial Of PRP(RTTNews) – Propanc Biopharma, Inc. (PPCB) a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, announced it has signed a Memorandum of Understanding (MOU) with Avance Clinical Pty Ltd, a full-service Contract Research Organization headquar
- RTTNews · Jul 7, 10:46 AM EDTPropanc Biopharma Signs MOU With Avance To Advance Phase 1b, FIH Of PRP In Solid Tumours; Stock Down(RTTNews) – Propanc Biopharma, Inc. (PPCB) announced that it has signed a Memorandum of Understanding (MOU) with Avance Clinical Pty Ltd, an Australia-based full-service Contract Research Organization, with the intention to collaborate for supporting the clinical delivery of Prop
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Propanc Biopharma, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.